NVS - Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer | Benzinga
Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies (TRTs), with three currently in clinical development.
The analysts Jeff Jones and Kyle Yang have initiated with an Outperform rating and a price target of $13.
The company's candidates are making their mark in the well-established yet competitive field of metastatic castration-resistant prostate cancer (mCRPC) and are also exploring more innovative targets applicable to various solid tumors.